Hepatitis A may not be on your radar, but with the current LA County outbreak, you may want to reacquaint yourself with this ...

Vir is holding off on advancing the combination therapy to Phase III trials in hepatitis B until it secures a development ...

The global hepatitis c testing market revenue was around US$ 1.8 billion in 2021 and is estimated to reach US$ 2.8 billion by 2031, growing at a compound annual growth rate (CAGR) of 5.3% during the ...

- Cash Position: Cash and cash equivalents were $101.6 million as of March 31, 2025, compared to $34.6 million as of December 31, 2024, bolstered by $76.4 million in gross proceeds from the first ...

Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...

Vir Biotechnology (NASDAQ:VIR) on Friday announced 24-week post-end-of-treatment data from a mid-stage trial for tobevibart ...

Vir Biotechnology, Inc. progresses HDV treatment with promising ECLIPSE program results. Click here to find out why VIR stock ...

Discover a recent study presented at EASL 2025 that explored the impact of opt-out testing for blood-borne viruses in ...

The researchers showed "super antibodies" from the man's blood prevented toxic damage from neurotoxins found in the venoms of 19 different snake species, including mambas and cobras. Even so ...

Uninsured or underinsured residents can get vaccinated at county Public Health clinics. Hepatitis A is a highly contagious liver infection caused by the hepatitis A virus. It can range from a mild ...

Hepatitis D is a type of viral hepatitis that affects around 48 million people worldwide. It is less common than other types of hepatitis that you might be more familiar with. Hepatitis D is thought ...

The researchers showed “super antibodies” from the man’s blood prevented toxic damage from neurotoxins found in the venoms of 19 different snake species. Scientists in the United States have ...